This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $60.16 in the latest trading session, marking a -1.26% move from the prior day.
ESG Investing Trend to Stay Strong Post Pandemic: 5 Top Picks
by Zacks Equity Research
Investing in ESG stocks bear lesser financial risks due to their focus on environment, employees and supply chain. They proved resilient during the coronavirus pandemic and will continue to surge.
Top Ranked Growth Stocks to Buy for June 9th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 9th
Powerful Proof Anyone Can Invest for an Early Retirement - June 08, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
AstraZeneca Reportedly Approaches Gilead for Potential Merger
by Zacks Equity Research
If AstraZeneca (AZN) and Gilead (GILD) were to combine into one, it would be the biggest health-care deal ever.
Bristol-Myers (BMY) Up 0.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
J&J's Darzalex Subcutaneous Version Gets Approval in Europe
by Zacks Equity Research
J&J (JNJ) announces approval of subcutaneous formulation of Darzalex for all current MM indications in first-line as well as relapsed/refractory multiple myeloma.
Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $60.89, marking a +1.13% move from the previous day.
Signs That Your Trading Will Ruin Your Retirement - June 04, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage study of Zeposia in patients with moderate-to-severe ulcerative colitis meets both its main goals.
Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Roche Tecentriq-Avastin Combo Gets FDA Nod for Liver Cancer
by Zacks Equity Research
FDA approves Roche's (RHHBY) sBLA seeking approval of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
FDA Okays AVEO's NDA Filing for Treating Renal Cell Carcinoma
by Zacks Equity Research
AVEO's new drug application submission for tivozanib as a treatment of relapsed or refractory renal cell carcinoma gets acceptance from the FDA. A decision is expected on Mar 31, 2021.
Zacks.com featured highlights include: Keurig Dr Pepper, Bristol-Myers Squib, Vistra Energy, IHS Markit and Campbell Soup
by Zacks Equity Research
Zacks.com featured highlights include: Keurig Dr Pepper, Bristol-Myers Squib, Vistra Energy, IHS Markit and Campbell Soup
Top Ranked Income Stocks to Buy for June 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 2nd.
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers
Buy These 5 Stocks With Impressive Sales Growth Right Away
by Swayta Shah
Sales growth can be considered by investors as a reliable metric for selecting profitable stocks amid the challenging operating backdrop.
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $59.72 in the latest trading session, marking a -0.15% move from the prior day.
Powerful Proof Anyone Can Invest for an Early Retirement - May 29, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN
by Kinjel Shah
Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.
Is Bristol-Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.
Bristol-Myers (BMY) Wins EC Approval for MS Drug Zeposia
by Zacks Equity Research
Bristol-Myers (BMY) gets EC nod for Zeposia for the treatment of adult patients with relapsing remitting multiple sclerosis.
Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How Trading Your Own Retirement Can Fleece Your Financial Future - May 27, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.